Table 3.

Summary of MCL1 inhibitors under clinical trials.

Compound, chemical structure, and institution	Potency (TR‐FRET)	Clinical trials a	Study	Administration	Indication	References
AZD5991 AstraZeneca	MCL1 K i = 0.2 nm BCL2 K i = 6.8 μm BCL‐xL K i = 18 μm BCLW K i = 25 μm BFL1 K i = 12 μm	NCT03218683	Phase I, monotherapy, and combination	IV	Refractory Hematological malignancies	[213]
AMG‐176 Amgen	MCL1 K i = 0.06 nm BCL2 K i = 0.95 μm BCL‐xL K i = 0.7 μm	NCT02675452	Phase I, monotherapy	IV	Relapsed or refractory MM/AML	[159]
		NCT03797261	Phase I, monotherapy with venetoclax	IV	AML/Lymphoma
AMG‐397 Amgen	Not disclosed	NCT03465540	Phase I, monotherapy	Oral	MM/AML/NHL	[214]
S64315/MIK665 Servier/Novartis	MCL1 K i = 1.2 nm	NCT02979366	Phase I, monotherapy	IV	AML/MDS	[156]
		NCT02992483	Phase I, monotherapy	IV	MM/Lymphoma
		NCT03672695	Phase I, combination with venetoclax	IV	AML/MDS
		NCT04629443	Phase II, combination with azacitidine	IV	AML
		NCT04702425	Phase I, combination with VOB560	IV	NHL/AML/MM
Structure not disclosed ABBV‐467 AbbVie	Not disclosed	NCT04178902	Phase I, monotherapy	IV	MM	Not disclosed
Structure not disclosed PRT1419 Prelude Therapeutics	Not disclosed	NCT04543305	Phase I, monotherapy	Oral	Refractory Hematological malignancies	Not disclosed
		NCT04837677	Phase I, monotherapy	IV	Relapsed or refractory solid tumors

^a From www.ClinicalTrials.gov.